About Matthew Gonda
Form D filings for Amytrx Therapeutics from 2015 to 2024 list Matthew Gonda as president and CEO, director.
Matthew Gonda first appears on SEC filings in 2015.
Experience
This experience comes from SEC filings. The years are when the filings name Matthew Gonda in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Matthew Gonda works with at each company, as listed on that company's latest Form D.
Amytrx Therapeutics, Inc. · Form D, Jan 31, 2024
LG
Lawrence Greer
Director
SJ
Satish Joshi
Director
MH
Michael Howell
Director
DC
Dennis Carlo
Director
RP
Raymond Pirtle
Director